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ORIGINAL RESEARCH • THORACIC IMAGING
In patients who have asthma, chronic airways disease typi-cally results in variable airflow obstruction that may be 
partially or completely reversed by using bronchodilators 
(1). Many people with asthma maintain stable lung func-
tion and bronchodilator reversibility over time, whereas a 
subset of patients may experience accelerated lung func-
tion decline and eventually lose postbronchodilator revers-
ibility (2–4). Recent epidemiologic studies showed that 
in up to 10% of people with asthma, airways disease may 
lead to chronic, persistent airflow obstruction and chronic 
obstructive pulmonary disease (5,6), but the mechanisms 
underlying these changes are not fully understood.
Airway remodeling caused by chronic inflammation 
has been suggested to mediate changes that result in air-
flow obstruction that is not bronchodilator reversible (7). 
Asthma involves both the small and large airways and it 
is difficult to measure small airway dysfunction by using 
spirometry measurements of the forced expiratory volume 
in 1 second (FEV1) because it is insensitive to peripheral 
airway changes.
The morphologic structure of remodeled and inflamed 
airways can be directly measured by using thoracic radio-
graphic CT (8–10), and airway function may also be viewed 
by using expiratory CT lucency of gas trapping (11,12) or 
parametric response mapping (13,14). Parametric response 
map gas trapping was shown (14) to be increased in par-
ticipants with severe asthma compared with participants 
with nonsevere asthma and control participants. Inhaled 
hyperpolarized gas MRI directly probes ventilation as a 
consequence of both central and peripheral airway func-
tion and has revealed the presence of nonrandom ventila-
tion defects (15) that are the functional consequences of 
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Background: Longitudinal progression to irreversible airflow limitation occurs in approximately 10% of patients with asthma, but it 
is difficult to identify patients who are at risk for this transition.
Purpose: To investigate 6-year longitudinal changes in hyperpolarized helium 3 (3He) MRI ventilation defects in study participants 
with mild-to-moderate asthma and identify predictors of longitudinal changes in postbronchodilator forced expiratory volume in 1 
second (FEV1) reversibility
Materials and Methods: Spirometry and hyperpolarized 3He MRI were evaluated in participants with mild-to-moderate asthma 
in two prospectively planned visits approximately 6 years apart. Participants underwent methacholine challenge at baseline 
(January 2010 to April 2011) and pre- and postbronchodilator evaluations at follow-up (November 2016 to June 2017). FEV1 
and MRI ventilation defects, quantified as ventilation defect volume (VDV), were compared between visits by using paired t tests. 
Participants were dichotomized by postbronchodilator change in FEV1 at follow-up, and differences between reversible and not-
reversible groups were determined by using unpaired t tests. Multivariable models were generated to explain postbronchodilator 
FEV1 reversibility at follow-up.
Results: Eleven participants with asthma (mean age, 42 years 6 9 [standard deviation]; seven men) were evaluated at baseline and 
after mean 78 months 6 7. Medications, exacerbations, FEV1 (76% predicted vs 76% predicted; P = .91), and VDV (240 mL 
vs 250 mL; P = .92) were not different between visits. In eight of 11 participants (73%), MRI ventilation defects at baseline were 
at the same location in the lung at follow-up MRI. In the remaining three participants (27%), MRI ventilation defects worsened 
at the same lung locations as depicted at baseline methacholine-induced ventilation. At follow-up, postbronchodilator FEV1 was 
not reversible in six of 11 participants; the concentration of methacholine to decrease FEV1 by 20% (PC20) was greater in FEV1-
irreversible participants at follow-up (P = .01). In a multivariable model, baseline MRI VDV helped to predict postbronchodilator 
reversibility at follow-up (R 2 = 0.80; P , .01), but PC20, age, and FEV1 did not (R 
2 = 0.63; P = .15).
Conclusion: MRI-derived, spatially persistent ventilation defects predict postbronchodilator reversibility 78 months 6 7 later for 
participants with mild-to-moderate asthma in whom there were no changes in lung function, medication, or exacerbations.
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airway remodeling, inflammation, and/or intraluminal plugging 
(16–18). In patients with asthma, MRI ventilation defects are 
spatially related to abnormally remodeled airways (16,17), posi-
tively correlated with disease severity (19), and improved in re-
sponse to bronchodilators (15,20). The size and spatial locations 
of MRI ventilation abnormalities persist over time (21,22) and 
are related to asthma exacerbations (23), asthma control, and 
quality of life (24).
Although epidemiologic studies (5,6,25) suggest that asthma 
progression to chronic obstructive pulmonary disease may be rela-
tively common, it is difficult to identify patients who are at risk. 
Because hyperpolarized helium 3 (3He) and xenon 129 (129Xe) 
MRI are sensitive tools to help simultaneously measure both small 
and large airway function, we hypothesized that MRI ventilation 
abnormalities would be predictive of future FEV1 bronchodila-
tor reversibility and, at the same time, ventilation defects would 
remain spatially persistent during follow-up. Accordingly, the pur-
pose of this study was to investigate 6-year longitudinal changes in 
hyperpolarized 3He MRI ventilation defects in study participants 
with mild-to-moderate asthma and identify predictors of longitu-
dinal changes in postbronchodilator FEV1 reversibility.
Materials and Methods
Study Participants and Design
Between January 2010 and April 2011, we consecutively re-
cruited study participants from a tertiary care pulmonary clinic 
who had mild-to-moderate asthma (ie, prescribed medium-
high dose inhaled corticosteroid or long-acting b agonist or 
less treatment for asthma controller medication) according to 
the Global Initiative for Asthma treatment step criteria (1), 
and were aged 18–70 years with less than 1 pack-year smok-
ing history. Participants provided written informed consent 
to an ethics-board-approved, Health Insurance Portability 
and Accountability Act–compliant, registered (ClinicalTrials.
gov: NCT02351141) protocol for baseline and 6-year follow-
up visits (November 2016–June 2017). Exclusion criteria in-
cluded the following: FEV1 greater than 80% predicted and 
concentration of methacholine required to decrease FEV1 by 
20% from baseline (PC20) greater than 8 mg/mL, claustropho-
bia, inability to undergo spirometry, body mass index greater 
than 40 kg/m2, and contraindications to MRI (ie, metal, elec-
tronic, or magnetic implants). Baseline measurements were 
previously reported (17) and focused on the cross-sectional 
analyses; in our study, we reported the longitudinal follow-up 
measurements after 6 years and compared them with baseline 
measurements. Data generated during our study are available 
from the corresponding author.
Spirometry, plethysmography, CT, and MRI were performed 
at both study visits. At baseline, participants underwent a metha-
choline challenge, with MRI and spirometry performed before 
methacholine, after methacholine, and after bronchodilator re-
covery, and plethysmography and CT before methacholine. At 
follow-up, participants underwent all tests before and after bron-
chodilator only (no methacholine challenge at follow-up), with 
CT performed after bronchodilator. We used electronic health 
records and participant self-reports to measure exacerbations and 
changes in medication during the study visit interval (26).
Pulmonary Function Tests and Methacholine 
Challenge
Spirometry was performed according to American Thoracic 
Society guidelines (27) by using a spirometer (ndd EasyOne; 
ndd Medizintechnik AG, Zurich, Switzerland). Plethysmogra-
phy was performed by using a plethysmograph (MedGraph-
ics Elite Series; MedGraphics Diagnostics, St Paul, Minn) to 
measure lung volumes and airways resistance. Methacholine 
challenge was performed according to American Thoracic So-
ciety guidelines (28) with the 2-minute tidal breathing method 
up to and including PC20 by using a breath-actuated nebulizer 
(AeroEclipse II; Trudell Medical International, London, On-
tario, Canada). Bronchodilation was achieved after four sepa-
rate doses of 100 mg of novo-salbutamol hydrofluoroalkane 
(Teva Novopharm, Toronto, Ontario, Canada) through a pres-
surized metered-dose inhaler by using a spacer (AeroChamber 
Plus; Trudell Medical International). Bronchodilator reversibil-
Abbreviations
FEV1 = forced expiratory volume in 1 second, PC20 = concentration 
of methacholine causing a 20% decrease in FEV1, VDV = ventilation 
defect volume
Summary
In study participants with mild-to-moderate asthma, MRI ventilation 
defect volume predicted reversibility of postbronchodilator forced 
expiratory volume in 1 second 6 years later.
Key Results
 n Helium 3 (3He) MRI ventilation defects at year 1 predicted bron-
chodilator reversibility 6 years later (R 2 = 0.80; P , .01).
 n In eight of 11 study participants, MRI ventilation defects re-
mained in the same location at the 6-year follow-up MRI.
 n In three of 11 participants, MRI ventilation defects showed clini-
cally significant worsening at the 6-year follow-up MRI in the 
same lung regions that had worsened in response to methacholine 
at year 1.
Figure 1: Study flowchart of patient inclusion and 
exclusion. Two participants were excluded because they 
did not have current asthma. ∗ Enrolled per Svenningsen 
et al (17).
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ded to 128 3 128; partial echo percentage, 62.5%; 15–17 sec-
tions; section thickness, 15 mm; no gap). 3He gas was polarized to 
30%–40% by using a commercial turn-key polarizer (HeliSpin; 
Polarean, Durham, NC). We performed 3He static ventilation 
MRI during 1.0-L breath-hold of hyperpolarized 3He diluted to 
25% by volume with N2 by using a single-channel rigid ellipti-
cal transmit-receive chest coil (Rapid Biomedical, Wuerzburg, 
Germany) and a two-dimensional multisection fast-gradient-
recalled echo sequence (partial echo acquisition; total acquisi-
tion time, 11 seconds; 3.8/1.0; flip angle, 7°; field of view, 40 3 
40 cm2; bandwidth, 48.8 kHz; 128 3 80 matrix, zero padded 
to 128 3 128; partial echo percentage, 62.5%; 15–17 sections; 
section thickness, 15 mm; no gap).
Quantitative MRI analysis was performed by a single ob-
server (R.L.E., with 4 years of experience) who was blinded to 
baseline and follow-up visits by using in-house segmentation 
software (smallest detectable difference [32] and minimal clini-
cally important difference [33]) in Matlab R2016a (Mathworks, 
Natick, Mass) as previously described (32). Static ventilation im-
ages were segmented by using three-dimensional k-means clus-
tering that classified voxel intensities into five clusters ranging 
from signal void or ventilation defects (cluster 1) to hyperintense 
signal (cluster 5; all ventilated volume clusters 2–5). Ventilation 
abnormalities were quantified as the ventilation defect volume 
(VDV) and as the ventilation defect percent (VDV normalized 
to the MRI-measured volume of the thoracic cavity). Repeat-
ability of MRI VDV and ventilation defect percent in this study 
ity of FEV1 was defined as a postbronchodilator increase of 200 
mL and 12% (29); participants were dichotomized as reversible 
or not reversible FEV1 at follow-up. The minimal clinically 
important difference for FEV1 was used to determine changes 
in FEV1 between visits as previously described (29,30). Par-
ticipants withheld asthma medications according to American 
Thoracic Society guidelines (28) before both visits as follows: 
short-acting b agonists were withheld for 8 hours, long-acting 
b agonists were withheld for 48 hours, and long-acting musca-
rinic agents were withheld for 24 hours.
MRI Parameters and Analysis
We performed anatomic proton (hydrogen 1 [1H]) and 3He 
static ventilation MRI at the coronal plane within 5 minutes 
by using a whole-body 3.0-T imager (Discovery MR750; GE 
Healthcare, Milwaukee, Wis) with broadband capability as pre-
viously described (31). Participants were instructed to inhale a 
gas mixture from a 1.0-L bag (Tedlar; Jensen Inert Products, 
Coral Springs, Fla) from functional residual capacity, and 15 
coronal sections were acquired in 8–15 seconds at breath-hold. 
We performed 1H MRI before hyperpolarized 3He during 1.0-L 
breath-hold of high purity, medical-grade nitrogen (N2; Spectra 
Gases, Alpha, NJ) by using the whole-body radiofrequency coil 
and a fast-spoiled gradient-recalled echo sequence (partial echo 
acquisition; total acquisition time, 8 seconds; repetition time 
msec/echo time msec, 4.7/1.2; flip angle, 30°; field of view, 
40 3 40 cm2; bandwidth, 24.4 kHz; 128 3 80 matrix, zero pad-
Table 1: Participant and MRI Measurements at Baseline and Follow-up
Parameter
Baseline Follow-up
P Value, 
Baseline vs 
Follow-up
All Participants  
(n = 11)
Stable VDV 
(n = 8)
Worse VDV  
(n = 3)
P  
Value
All Participants  
(n = 11)
Stable VDV  
(n = 8)
Worse VDV  
(n = 3)
P  
Value
Age (y) 42 6 9 42 6 10 43 6 6 .92 49 6 9 49 6 10 49 6 7 ..99 ...
No. of women 4 2 2 ... 4 2 2 ... ...
BMI (kg/m2) 27 6 4 26 6 4 29 6 2 .33 28 6 4 27 6 5 29 6 2 .48 .03
FVC* 87 6 13 88 6 13 85 6 14 .78 85 6 14 87 6 15 79 6 5 .39 .47
FEV1 (L) 2.80 6 0.86 2.89 6 1.00 2.56 6 0.37 .60 2.65 6 0.85 2.76 6 0.92 2.35 6 0.69 .51 .19
FEV1* 76 6 12 76 6 14 75 6 7 .94 76 6 12 78 6 12 72 6 11 .53 .91
FEV1/FVC (%) 70 6 7 69 6 7 72 6 6 .52 73 6 8 72 6 7 74 6 11 .69 .13
RV* 126 6 20 127 6 14 124 6 26 .85 136 6 26 136 6 18 135 6 48 .96 .02
TLC* 103 6 9 104 6 7 101 6 13 .55 104 6 11 105 6 9 102 6 15 .71 .56
RV/TLC* 123 6 18 123 6 16 122 6 24 .98 129 6 17 129 6 15 128 6 27 .96 .08
Raw* 172 6 68 177 6 70 160 6 75 .75 178 6 44 159 6 35 230 6 6 .01 .77
VDV (mL) 240 6 180 290 6 180 120 6 130 .19 250 6 210 180 6 110 440 6 330 .06 .92
VDP (%) 5 6 3 5 6 3 3 6 2 .27 5 6 4 3 6 2 8 6 6 .31 .99
ICS dose (mg/day)† 400 (0–1600) 400 (0–800) 600 (400–1600) .19 400 (0–1600) 400 (0–800) 800 
(0–1600)
.50 .32
OCS dose (mg/day)0 0 0 ... 0 0 0 ... ...
Note.—Unless otherwise indicated, data are mean 6 standard deviation. Mean follow-up was 78 months 6 7 (median, 79 months; range, 
68–87 months) from baseline. BMI = body mass index, FEV1 = forced expiratory volume in 1 second, FVC = forced vital capacity, ICS = 
inhaled corticosteroid, OCS = oral corticosteroid, Raw = airways resistance, RV = residual volume, TLC = total lung capacity, VDP = ventila-
tion defect percent, VDV = ventilation defect volume.
* Data are percent predicted.
† Data are median shown as budesonide equivalent; data in parentheses are range. Ten participants were prescribed inhaled corticosteroid 
with long-acting b agonist.
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induced changes. At baseline, CT was performed 
at a 4–10 cm axial region of interest with visually 
obvious ventilation defects as previously described 
(17) to reduce radiation dose. At follow-up, a full 
CT image of the thorax was acquired by using a 
low-dose protocol as previously described (34).
Thoracic CT images were analyzed by using a 
commercial workstation (Pulmonary Workstation 
2.0; Vida Diagnostics, Coralville, Iowa) to segment 
and measure the three-dimensional airway tree. 
The measurements between visits were compared 
within the region of the partial CT image acquired 
at baseline.
Statistical Analysis
Data were tested for normality by using Shapiro-
Wilk tests with commercially available software 
(SPSS Statistics 25.0; IBM, Armonk, NJ). When 
data were not normally distributed, they were log 
transformed. Measurements for each visit were 
compared by using paired t tests, and bronchodi-
lator-reversible and bronchodilator-not-reversible 
subgroup measurements were compared by us-
ing unpaired t tests (SPSS; IBM). MRI VDV and 
ventilation defect percent repeatability were de-
termined by using the coefficient of variation and 
two-way mixed effects intraclass correlation coeffi-
cient (SPSS; IBM). Univariable relationships were 
evaluated by using Pearson correlation coefficients 
(r) in commercially available software (GraphPad 
Prism 7.00; GraphPad Software, La Jolla, Calif ) 
for follow-up postbronchodilator change in FEV1 
with baseline measurements related to the metha-
choline challenge. These included FEV1 and VDV 
before methacholine with differences between chal-
lenge states (ie, postmethacholine challenge 2 pre-
methacholine challenge) and PC20. On the basis 
of univariable relationships, multivariable models 
were generated (SPSS; IBM) by using the enter ap-
proach to determine the largest influence for pre-
dicting FEV1 bronchodilator reversibility (postbronchodilator 
change in FEV1 in milliliters) at follow-up for the following two 
models: (a) baseline variables that had significant univariable re-
lationships with postbronchodilator change in FEV1 follow-up; 
and (b) age, FEV1, and PC20 at baseline, which have been shown 
(2,4,35) to predict future bronchodilator reversibility, along with 
baseline VDV. The regression coefficients for the variables in the 
multivariable models were expressed as standardized b. Results 
were considered statistically significant when the probability of 
making a type I error was less than 5% (P , .05).
Results
Study Participants
The study flowchart is provided in Figure 1; 26 participants 
were enrolled (17) but two participants (8%) did not have 
asthma and were excluded. Of 24 participants who com-
was evaluated by a single observer (R.L.E., blinded for segmen-
tation) in five randomly selected participants. Blinded partici-
pant selection and randomization between repeated segmenta-
tion rounds was provided by an additional observer who did not 
participate in the data analysis. Quantitative, clinically relevant 
MRI changes were evaluated by using the following equation: 
VDV . |110| mL, which is the published minimal clinically 
important difference for VDV (33), where VDV is change in 
VDV. The spatial locations of ventilation defects were visually 
and qualitatively compared between visits (R.L.E.).
CT Parameters and Analysis
Thoracic CT was performed within 10 minutes of MRI by us-
ing a 64-section system (LightSpeed VCT; GE Healthcare) at 
breath-hold after inhalation of 1.0 L of N2 from functional 
residual capacity to volume match to MRI. Participants were 
transported from MRI to CT by wheelchair to avoid exercise-
Figure 2: Images show helium 3 (3He) MRI ventilation in a 28-year-old man (par-
ticipant S03) with mild-to-moderate asthma and stable ventilation between baseline 
and follow-up. A, Center coronal section 3He ventilation MRI (cyan, administered 
as an inhaled contrast agent) coregistered to anatomic hydrogen 1 (1H) MRI (gray 
scale) for baseline premethacholine challenge (pre-MCh) and follow-up before and 
after bronchodilator (pre-BD and post-BD, respectively). Persistent defects between 
visits are shown (arrows). B, Follow-up three-dimensional 3He MRI shows ventilation 
coregistered to CT with three-dimensional airway tree at oblique angle. Inset (coro-
nal view) shows RB8 bronchus subsegmental bifurcation. Inferior daughter branch 
leading to persistent defect between baseline and follow-up appears narrowed 
compared with superior daughter branch. Participant S03 was a man with mild-to-
moderate asthma (baseline and follow-up, respectively: age, 28 years and 35 years; 
forced expiratory volume in 1 second, 3.97 L and 4.19 L; ventilation defect volume, 
340 mL and 260 mL).
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traclass correlation coefficient of 1.00 (95% confidence inter-
val: 0.98, 1.00) for both VDV and ventilation defect percent. 
For eight study participants (of 11 participants; 73%), MRI 
ventilation defects remained in the same location at the 6-year 
follow-up MRI and were similar in size (change in VDV be-
tween visits, ,110 mL). Figure 2 shows 3He MRI ventilation 
at baseline and follow-up and airway corresponding to a per-
sistent defect for a representative participant with stable VDV 
(participant S03). A subsegmental bifurcation in the RB8 
bronchus showed narrowing in the inferior daughter branch 
compared with the superior daughter branch. For the remain-
ing three participants (of 11; 27%), follow-up prebronchodila-
tor ventilation defects were visually and quantitatively larger 
than baseline defects (change in VDV between visits, .110 
mL) and were in the same lung regions as baseline postmetha-
choline ventilation defects. Figure 3 shows 3He MRI ventila-
tion and airway corresponding to worsened follow-up defect 
for a representative participant with worse VDV at follow-up 
(participant S01). The LB8 bronchus leading to the worsened 
follow-up defect was abruptly truncated.
Table 2 shows CT airway measurements including airway 
wall area percent, lumen area, wall thickness, and number of 
mucus plugs at baseline and follow-up, and total airway count 
at follow-up. For all participants at baseline versus follow-up, 
mean wall area percent (70% 6 2 vs 69% 6 1, respectively; P 
= .14) and wall thickness (28.3 mm 6 2.1 vs 27.8 mm 6 3.3, 
respectively; P = .66) were not different, whereas mean lumen 
pleted the baseline visit, nine partici-
pants (35%) were lost to follow-up 
because they moved farther than 
500 km away or could not be con-
tacted, and four participants (15%) 
declined the follow-up visit. In to-
tal, 11 participants (seven men and 
four women) with mild-to-mod-
erate asthma (Global Initiative for 
Asthma treatment steps 1–4 [1]) 
were evaluated twice within mean 
78 months 6 7 (standard deviation; 
median, 79 months; range, 68–87 
months). Mean participant age was 
42 years 6 9 at baseline (men, 41 
years 6 10; women, 44 years 6 6; 
P = .63) and 49 years 6 9 at follow-
up (men, 48 years 6 10; women, 51 
years 6 7; P = .62). Table E1 (online) 
shows the baseline measurements for 
participants who completed longi-
tudinal follow-up (11 participants; 
42%) and those who were lost to 
follow-up (15 participants; 58%). 
Participants who completed longitu-
dinal follow-up compared with those 
who did not complete longitudinal 
follow-up were older (mean age, 42 
years 6 9 vs 28 years 6 9, respec-
tively; P , .01) with worse lung 
function overall (all P , .05 except forced vital capacity and 
total lung capacity) and ventilation defect percent (5% 6 4 
vs 2% 6 1, respectively; P , .01).
Table 1 provides demographic, pulmonary function test, and 
MRI measurements. A participant listing is provided in Table 
E2 (online) and a detailed list of asthma medications is provided 
in Table E3 (online). Between the baseline and follow-up visits, 
mean body mass index (27 kg/m2 6 4 vs 28 kg/m2 6 4, respec-
tively; P = .03) and mean residual volume (126% predicted 6 
20 vs 136% predicted 6 26, respectively; P = .02) were different; 
all other measurements were not different (P . .05). All partici-
pants were never-smokers (0 pack-years) and none reported an 
asthma exacerbation between study visits. All participants except 
one (participant S06) were prescribed inhaled corticosteroids 
and/or inhaled corticosteroid with long-acting b agonist at base-
line. During the interval between visits, nine participants (82%) 
remained on the same type and dose of medication whereas a 
single participant (participant S03) changed the type of inhaled 
corticosteroid and long-acting b agonist controller while ad-
ministered the same daily inhaled corticosteroid dose. Against 
medical advice, a single participant (participant S11) refused to 
self-administer prescribed asthma medications during the inter-
val between the baseline and follow-up visits.
3He MRI Ventilation at Baseline and Follow-Up
MRI measurements were highly repeatable with coefficient of 
variation of 5% (95% confidence interval: 3%, 7%) and in-
Figure 3: Images show helium 3 (3He) MRI ventilation in a 36-year-old woman (participant 
S01) with mild-to-moderate asthma and worse ventilation at 6-year follow-up. A, Center coro-
nal section 3He ventilation MRI (cyan, administered as an inhaled contrast agent) coregistered 
anatomic hydrogen 1 MRI (gray scale) for baseline premethacholine challenge (pre) and after 
methacholine challenge (post), and follow-up before (pre) and after (post) bronchodilator. Wors-
ened defects were shown between visits (arrows). B, Follow-up three-dimensional 3He MRI shows 
ventilation coregistered to CT with three-dimensional airway tree at oblique angle. Inset on top 
(coronal view) shows LB8 bronchus leading to worsened follow-up defect. Lumen appears clear 
and open but is abruptly truncated within three sections anteriorly (inset on bottom). Participant 
S01 was a woman with mild-to-moderate asthma (baseline and follow-up, respectively: age, 36 
and 41 years; forced expiratory volume in 1 second, 2.28 L and 1.71 L; ventilation defect vol-
ume, 270 mL and 780 mL).
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chodilator change in FEV1. All other measurements were not 
correlated with postbronchodilator change in FEV1 (Table E5 
[online]; P . .05).
Multivariable Analysis
We generated multivariable models to explore potential pre-
dictors of postbronchodilator FEV1 reversibility at follow-up 
(Table 4). Baseline premethacholine challenge VDV (standard-
ized b = 0.89; P = .01) and premethacholine challenge–to–
postbronchodilator change in VDV (standardized b = 0.58; 
P = .03) predicted postbronchodilator change in FEV1 (model 
1: R2 = 0.80; P = .01). A second model including FEV1, age, 
and PC20 did not predict postbronchodilator change in FEV1 
(model 2: R2 = 0.63; P = .15).
Discussion
Recent epidemiologic studies (5,6,25) showed that in up to 10% 
of people with asthma, airways disease may lead to chronic, per-
sistent airflow obstruction and chronic obstructive pulmonary 
disease but the underlying mechanisms of these changes are not 
fully understood. In our study, we investigated 6-year longitudi-
nal changes in hyperpolarized helium 3 (3He) MRI ventilation 
defects in individuals with mild-to-moderate asthma and sought 
to identify predictors of longitudinal changes in postbronchodi-
lator forced expiratory volume in 1 second (FEV1) reversibility. 
We showed that MRI ventilation helps to predict long-term post-
bronchodilator FEV1 reversibility in mild-to-moderate asthma. 
We observed the following: (a) negligible postbronchodilator 
area was greater at follow-up (baseline vs follow-up, 5.4 mm2 
6 1.9 vs 6.9 mm2 6 1.6, respectively; P , .001). Airway 
measurements were not different between subgroups (P . 
.05). One participant (participant S01) had three subsegmen-
tal mucus plugs at follow-up in the LB4, RB2, and RB10 
bronchi, which did not correspond to ventilation defects.
FEV1 and Ventilation Defects Postbronchodilator 
Reversibility Measurements
Table 3 shows FEV1 and MRI ventilation defects postbron-
chodilator reversibility measurements for each participant by 
groups with stable and worse VDV at follow-up. At follow-
up, six participants were not FEV1 bronchodilator reversible 
and eight participants had marginal MRI ventilation defect 
(change in VDV was greater than 2110 mL) bronchodila-
tor reversibility. We compared measurements between FEV1 
reversible and not reversible participant groups and, as shown 
in Figure 4, PC20 was greater (ie, more normal) in partici-
pants who were not reversible (Fig 4, A; P = .01), whereas the 
ratio of residual volume to total lung capacity was greater in 
participants who were bronchodilator reversible (Fig 4, B; 
P , .001). All other measurements were not different between 
reversible and not reversible participant groups (Table E4 
[online]; P . .05). We also plotted baseline measurements 
against postbronchodilator change in FEV1 at follow-up, and 
the univariable relationships are shown in Figure 4, C, D. 
PC20 (r = 20.61; P = .049) and premethacholine challenge 
VDV (r = 0.67; P = .02) at baseline were related to postbron-
Table 2: CT Measurements
Participant
Baseline (n = 11) Follow-up (n = 11)
WA (%) LA (mm2) WT (mm) Mucus WA% LA (mm2) WT (mm) Mucus TAC
Stable VDV at follow-up (n = 8)
 S02 69 6.7 28.3 0 69 8.8 24.5 0/0 170
 S03 72 4.8 28.5 0 70 5.9 27.2 0/0 130
 S04 72 3.5 25.7 0 69 6.0 25.3 0/0 166
 S06 72 5.7 28.7 0 67 7.8 23.6 0/0 145
 S07 72 4.9 27.0 0 69 7.1 27.3 0/0 180
 S08 69 3.0 24.5 0 69 4.5 25.3 0/0 202
 S09 74 4.3 31.6 0 71 6.5 29.3 0/0 165
 S10 69 6.7 28.3 0 68 7.8 29.7 0/0 141
 Mean 71 6 2 5.0 6 1.4 27.8 6 2.1 … 69 6 1 6.8 6 1.4 26.5 6 2.2 … 162 6 23
Worse VDV at follow-up (n = 3)
 S01 70 3.4 27.6 0 72 4.5 26.3 1/3 114
 S05 66 3.8 29.3 0 71 5.7 31.5 0/0 224
 S11 69 6.8 28.6 0 67 8.2 31.1 0/0 196
 Mean 68 6 2 4.7 6 1.9 28.5 6 0.9 … 70 6 3 6.1 6 1.9 29.7 6 2.9 … 178 6 57
Group differences (n = 11)
 P value .12 .87 .72 … .66 .30 .59 … .51
 Mean 70 6 2 5.4 6 1.9 28.3 6 2.1 … 69 6 1 6.9 6 1.6 27.8 6 3.3 … 167 6 33
 Difference from baseline  
  (P value)
.14 ,.001 .66 … …
Note.—Mean data are 6 standard deviation. Measurements are matched for segments within partial CT images acquired at baseline, except 
mucus plugging at follow-up shown as matched partial CT/whole thoracic CT. Mucus indicates mucus plugging. LA = lumen area, TAC = 
total airway count, VDV = ventilation defect volume, WA = wall area, WT = wall thickness.
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The prevalence of negligible bronchodilator reversibility in 
our participant cohort (six of 11; 55%) was higher than previ-
ously reported in epidemiologic studies (5,6). In all but one of 
these participants, there were no changes in medication (except 
for participant S11 who refused prescribed inhaled corticoste-
roid and long-acting b agonist) or exacerbations. Moreover, at 
follow-up, two participants in this subgroup (participants S06 
and S10) met the criteria for fixed airflow obstruction consistent 
with chronic obstructive pulmonary disease (36) and two others 
(participants S05 and S11) had worse VDV at follow-up. Airway 
remodeling caused by chronic inflammation has been suggested 
to mediate changes that result in airflow obstruction not reversed 
by bronchodilators (7) and patients with asthma who do not un-
dergo regular treatment may progress to irreversible obstruction 
(4). We did not test for airway inflammation and therefore it is 
possible that inadequately controlled inflammation was respon-
sible for the lack of reversibility consistent with our finding at 
CT of mucus plugs in one participant.
For two participants (participants S04 and S08) there was 
poorly reversible postbronchodilator VDV alongside physiologi-
cally relevant FEV1 reversibility, and in participant S11, who 
stopped all asthma medications, there was neither FEV1 nor 
reversibility in six of 11 participants at follow-up, (b) MRI ven-
tilation defects at baseline predicted follow-up postbronchodila-
tor reversibility (R2 = 0.80; P = .01), (c) MRI ventilation defects 
persisted in the same spatial locations 6.5 years later, and (d) 
ventilation defects worsened in three of 11 participants in the 
same lung regions that previously worsened during methacho-
line challenge 6.5 years before.
MRI ventilation defects persisted in the same spatial loca-
tions at follow-up. For three participants (participants S01, 
S05, and S11), ventilation defects also worsened in the same 
spatial regions that worsened during a methacholine challenge 
approximately 6.5 years before. Previous studies evaluated MRI 
ventilation defects for up to approximately 1.5 years (21,22) 
and revealed spatially persistent defects (21), suggesting that 
fixed asthma airway abnormalities are spatially heterogeneous. 
We also evaluated CT airway measurements to investigate the 
underlying pathophysiologic structures of persistent and wors-
ening ventilation defects, which showed interindividual differ-
ences and mucus plugs in a single participant who worsened. 
However, there was no spatial relationship between ventilation 
worsening and mucus plugs in this participant with mild-to-
moderate asthma.
Table 3: Changes in Forced Expiratory Volume in 1 second and Ventilation Defects
Participant
Baseline PostBD 2  
PreMCh Challenge
Baseline PostBD 2  
PostMCh Challenge
Follow-up PostBD 2  
PreBD Challenge
Change in  
FEV1 (mL)
Change in  
VD (mL)
Change in  
FEV1 (mL)
Change in  
VD (mL)
Change in FEV1 
(mL)
Change in VD 
(mL)
Stable VDV at  
follow-up (n = 8)
 S02  2520 ( 215)  2190 ( 23) +780 (+35)  2420 ( 27) +680 (+24)  2200 ( 24)
 S03 +380 (+10)  2120 ( 22) +1360 (+45)  21710 ( 225) +220 (+5)*  290 ( 22)*
 S04 +30 (+2)  210 (0) +360 (+37)  280 ( 22) +220 (+15)  220 (0)*
 S06 +70 (+3) +10 (0) +810 (+43)  21150 ( 219) +150 (+5)*  210 (0)*
 S07  290 ( 22)  2210 ( 24) +1080 (+53)  2870 ( 211) +950 (+37)  2250 ( 22)
 S08 +470 (+26)  230 ( 21) +1010 (+81)  2230 ( 24) +260 (+14)  210 (0)*
 S09  2350 ( 29)  270 ( 22) +650 (+21)  2340 ( 25) +400 (+11)*  250 ( 22)*
 S10  230 ( 21) +10 (0) +580 (+29)  2630 ( 29) +60 (+2)* +20 (0)*
 Mean  210 6 330  
(+2 6 12)
 280 6 120  
( 21 6 3)
+830 6 310  
(+43 6 18)
 2680 6 480  
( 210 6 7)
+370 6 300  
(+14 6 11)
 280 6 100  
( 21 6 2)
Worse VDV at  
follow-up (n = 3)
 S01  2110 ( 25) +190 (+5) +800 (+58)  21040 ( 219) +1030 (+60)  2580 ( 211)
 S05 +200 (+7)  260 (0) +600 (+23)  2430 ( 26) +160 (+5)*  2100 ( 21)*
 S11  2140 ( 26) +40 (+1) +740 (+48)  2340 ( 27) +110 (+5)*  240 ( 21)*
 Mean  220 6 190  
( 21 6 7)
+60 6 130  
(+2 6 3)
+710 6 100  
(+42 6 18)
 2600 6 380  
( 210 6 7)
+430 6 520  
(+23 6 32)
 2240 6 300  
( 24 6 6)
All participants  
(n = 11)
Mean  210 6 270  
(+1 6 10)
 230 6 100  
(0 6 2)
+760 6 270  
(+40 6 18)
 2570 6 500  
( 29 6 8)
+300 6 370  
(+14 6 18)
 2100 6 160  
( 22 6 3)
Note.—FEV1 data in parentheses are percent change and VD data in parentheses are change in ventilation defect percent; mean data are 
6 standard deviation. Change in FEV1 shown as absolute difference in milliliters and as a percent of baseline. Change in VD shown as 
absolute VDV difference in milliliters and as absolute ventilation defect percent difference. BD = bronchodilator, FEV1 = forced expiratory 
volume in 1 second, MCh = methacholine challenge, VD = ventilation defect, VDV = VD volume.
* Not reversible FEV1 (n = 6) and VDV (n = 8).
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VDV postbronchodilator reversibility and 
ventilation defects worsened at follow-up. 
These findings are consistent with unresolved 
small airway abnormalities or mucus plugs 
(37) leading to persistent ventilation defects 
that are not reversed by using salbutamol, 
which mainly has receptors in the central 
airways. This could be consistent with air-
way inflammation (18) and suggests that 
irreversible FEV1 and worsening ventilation 
defects may result from inadequate treatment 
and/or poor adherence to prescribed asthma 
medication.
MRI VDV at baseline predicted broncho-
dilator reversibility at follow-up whereas age, 
PC20, and FEV1 did not predict bronchodila-
tor reversibility. Although baseline VDV had 
the greatest relative influence, the difference 
between ventilation defects before adminis-
tration of methacholine and postchallenge 
recovery (postBD 2 PreMCh = change in 
VDV, where postBD indicates after bron-
chodilator and preMCh indicates before 
methacholine challenge) also significantly 
contributed. Abnormal FEV1 and reduced 
postbronchodilator FEV1 reversibility were 
previously shown to predict postbronchodi-
lator FEV1 reversibility (4). Diminished (4) 
and augmented (2,35) airway hyperrespon-
siveness were also shown to predict FEV1 
decline and irreversible airflow obstruction 
in people with asthma. Severe airway hyper-
responsiveness was previously suggested (4) 
to have a protective effect on the airways by 
preventing airway narrowing, thereby pre-
serving bronchodilator reversibility. Whereas 
postbronchodilator FEV1 changes after ad-
ministration of methacholine have been 
evaluated before (38), to our knowledge, 
this is the first exploration of the potential 
longitudinal consequence of ventilation de-
fects induced by using methacholine. It is 
counterintuitive that diminished ventilation 
at baseline predicted postbronchodilator re-
versibility 6 years later. MRI ventilation de-
fects can be caused by large and small airway 
smooth muscle abnormalities, inflamma-
tion, and/or intraluminal mucus plugging 
(17,18,36); that baseline ventilation defects 
and the postbronchodilator change in venti-
lation defects after a methacholine challenge 
predict future FEV1 reversibility suggests that 
it is airway smooth muscle abnormalities 
and not inflammation or mucus plugging 
that drive MRI-based predictions of future 
postbronchodilator reversibility. However, 
the near complete lack of mucus plugs in the 
Figure 4: Graphs show group differences and univariable relationships for postbroncho-
dilator (BD) forced expiratory volume in 1 second (FEV1) reversibility. A, Baseline concentra-
tion of methacholine required to decrease FEV1 by 20% (PC20; log scale) was lower (ie, 
worse) in FEV1-reversible participants (P = .01) and, B, baseline residual volume (RV)–to–
total lung capacity (TLC) ratio (RV/TLC) was greater in reversible participants (P , .001). 
C, Natural logarithm of PC20 (lnPC20; r = 20.61; P = .049) and, D, premethacholine 
challenge (preMCh) VDV (r = 0.67; P = .02) were related to BD change in FEV1 (FEV1) at 
follow-up.
Table 4: Multivariable Model to Predict Bronchodilator Reversibility
Parameter
Unstandardized  
B Value
Standardized  
b Value P Value
Model 1
 Baseline PreMCh VDV 1.86* 6 0.47 0.89* .01
 Baseline PostBD 2 PreMCh  
  Change in VDV
1.80* 6 0.67 0.58* .03
 PC20 (mL
2/mg)†  20.11 6 0.05  20.41 .05
Model 2
 Baseline PreMCh VDV 1.15* 6 0.67 0.55* .14
 Baseline PreMCh FEV1  20.01* 6 0.01  20.14* .72
 Age (mL/y)  20.01 6 0.02  20.26 .54
 PC20 (mL
2/mg)†  20.08 6 0.10  20.29 .48
Note.—Model 1 is FEV1 reversibility at follow-up (n = 11; R
2 = 0.80; P , .01); 
model 2 is FEV1 reversibility at follow-up (n = 11; R
2 = 0.63; P = .15). B values are 6 
standard error. BD = bronchodilator, FEV1 = forced expiratory volume in one second, 
MCh = methacholine challenge, PC20 = concentration of methacholine causing 20% 
decrease in FEV1, VDV = ventilation defect volume.
* Unitless because independent and dependent variables have the same units.
† Log-transformed PC20. For all models, the predicted dependent variable was BD 
change in FEV1 in milliliters at follow-up (FEV1postBD 2 FEV1preBD, where postBD 
indicates after BD and preBD indicates before BD). Percent predicted was used for 
preMCh FEV1 to account for age, sex, height, and race/ethnicity differences, and 
absolute differences in milliliters were used for change in FEV1.
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participants studied here means we cannot test the role of mucus 
in our longitudinal findings. Nevertheless, these results highlight 
the utility and sensitivity of MRI ventilation measurements for 
hypothesis-driven, mechanistic studies, especially when com-
bined with pulmonary function tests and thoracic CT. It is im-
portant to point out that MRI and CT are complementary. In 
other words, MRI in combination with CT provides a way to 
discern the airway structural and luminal determinants of venti-
lation abnormalities in asthma.
We acknowledge the small sample size as a limitation, and 
the fact that this study was limited to two time points, both of 
which limited the generalizability of the multivariable models. 
Baseline and follow-up MRI evaluations were also different, but 
this allowed us to explore different relationships between airway 
hyperresponsiveness, ventilation defects, and bronchodilator re-
versibility. Finally, we recognize that, compared with 3He MRI, 
129Xe MRI offers a less costly and highly sensitive alternative to 
measure small airway function (20), and by using 129Xe MRI, we 
would expect similar if not more sensitive detection of ventila-
tion defects.
In study participants with mild-to-moderate asthma, MRI 
ventilation defect volume predicted reversibility of postbron-
chodilator forced expiratory volume in 1 second 6 years later, 
suggesting that pulmonary functional MRI may help to identify 
patients at risk for the transition from asthma to fixed airflow 
obstruction and chronic obstructive pulmonary disease.
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